Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100OZY9
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥71.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥936m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥993m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥993m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥427m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥427m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥195.3bnat 2022-06-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥199.1bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2022-06-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥49.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.272021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥1.7bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥278m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.2bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥451m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥77.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥71.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
AssetsPrior1YearInstant178753000000JPY
AssetsCurrentQuarterInstant195341000000JPY
Accounts payable tradePrior1YearInstant48513000000JPY
Accounts payable tradeCurrentQuarterInstant59066000000JPY
Electronically recorded obligations operating clPrior1YearInstant2862000000JPY
Electronically recorded obligations operating clCurrentQuarterInstant2907000000JPY
Short term loans payablePrior1YearInstant1000000000JPY
Short term loans payableCurrentQuarterInstant1500000000JPY
Current portion of long term loans payablePrior1YearInstant12366000000JPY
Current portion of long term loans payableCurrentQuarterInstant12871000000JPY
Income taxes payablePrior1YearInstant1800000000JPY
Income taxes payableCurrentQuarterInstant959000000JPY
Provision for bonusesPrior1YearInstant3861000000JPY
Provision for bonusesCurrentQuarterInstant2114000000JPY
Provision for directors bonusesPrior1YearInstant45000000JPY
Provision for directors bonusesCurrentQuarterInstant－JPY
Other clPrior1YearInstant8483000000JPY
Other clCurrentQuarterInstant11669000000JPY
Current liabilitiesPrior1YearInstant78931000000JPY
Current liabilitiesCurrentQuarterInstant91089000000JPY
Long term loans payablePrior1YearInstant41531000000JPY
Long term loans payableCurrentQuarterInstant45070000000JPY
Provision for directors retirement benefitsPrior1YearInstant71000000JPY
Provision for directors retirement benefitsCurrentQuarterInstant74000000JPY
Net defined benefit liabilityPrior1YearInstant2276000000JPY
Net defined benefit liabilityCurrentQuarterInstant2314000000JPY
Other nclPrior1YearInstant3065000000JPY
Other nclCurrentQuarterInstant3894000000JPY
Noncurrent liabilitiesPrior1YearInstant46944000000JPY
Noncurrent liabilitiesCurrentQuarterInstant51354000000JPY
LiabilitiesPrior1YearInstant125876000000JPY
LiabilitiesCurrentQuarterInstant142444000000JPY
Capital stockPrior1YearInstant3953000000JPY
Capital stockCurrentQuarterInstant3953000000JPY
Capital surplusPrior1YearInstant10926000000JPY
Capital surplusCurrentQuarterInstant10926000000JPY
Retained earningsPrior1YearInstant41507000000JPY
Retained earningsCurrentQuarterInstant41523000000JPY
Treasury stockPrior1YearInstant-3500000000JPY
Treasury stockCurrentQuarterInstant-3500000000JPY
Shareholders equityPrior1YearInstant52887000000JPY
Shareholders equityCurrentQuarterInstant52903000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-10000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-6000000JPY
Valuation and translation adjustmentsPrior1YearInstant-10000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant-6000000JPY
Net assetsPrior1YearInstant52876000000JPY
Net assetsCurrentQuarterInstant52897000000JPY
Liabilities and net assetsPrior1YearInstant178753000000JPY
Liabilities and net assetsCurrentQuarterInstant195341000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass